Article No
LS-C11578-1
PR / Progesterone Receptor
Progesterone Receptor antibody LS-C11578 is an unconjugated mouse monoclonal antibody to human Progesterone Receptor (PR). Validated for IHC and WB.
Antibodies Primary
Specifications
| NCBI Number | 5241 |
| Application | IHC, WB |
| Article No | LS-C11578-1 |
| Country Availability | SE, FI, DK, NO, FO, GL |
| Clone | 1A6 |
| Clone Type | monoclonal |
| Conjugation | Unconjugated |
| Description | Progesterone Receptor antibody LS-C11578 is an unconjugated mouse monoclonal antibody to human Progesterone Receptor (PR). Validated for IHC and WB. |
| Recommended Dilution | IHC-P (1:40), WB (1:25 - 1:50) |
| Supplier | LifeSpan Biosciences |
| Entrez Gene ID | 5241 |
| Gene Symbol | PGR |
| Immunogen | Synthetic peptide derived from human progesterone receptor sequence. |
| Isotype | IgG1 |
| Notes | Progesterone Receptor antibody LS-C11578 is an unconjugated mouse monoclonal antibody to human Progesterone Receptor (PR). Validated for IHC and WB. |
| Alias Names | PGR, NR3C3, PR, Progesterone receptor |
| Product Type | Antibodies Primary |
| Protocol | Immunohistology: Immediate fixation in Zamboni's fixative recommended. This product requires antigen retrieval using heat treatment prior to staining of paraffin sections. Sodium citrate buffer pH6.0 is recommended for this purpose. |
| Purification | Tissue culture supernatant |
| Shipping Information | RT |
| Size | 1 ml |
| Source / Host | mouse |
| Species Reactivity | human |
| Storage | -20°C |
| Substrate / Buffer | 15mM sodium azide |
| Technical Specifications | Recognizes the human progesterone receptor which is a member of the steroid family of nuclear receptors. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient's prognosis and the effectiveness of hormonal therapy. |
| Product Page Updated | 2024-04-12T06:35:05.844Z |
| Volume | 1 ml |
